PKI-166

• Description :

  PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H301

• Target :

  EGFR

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pki-166.html

• Purity :

  98.92

• Solubility :

  DMSO : ≥ 125 mg/mL

• Smiles :

  OC1=CC=C(C2=CC3=C(N=CN=C3N2)N[C@@H](C4=CC=CC=C4)C)C=C1

• Molecular Formula :

  C20H18N4O

• Molecular Weight :

  330.38

• Precautions :

  H301

• References & Citations :

  [1]Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 Jun 1;60 (11) :2926-35.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [187724-61-4]